152 results about "Paliperidone" patented technology

The present invention provides a method of treating patients in need of treatment with long acting injectable paliperidone palmitate formulations.

The present application provides a method for treating patients in need of psychiatric treatment, wherein said patient misses a stabilized dose of a monthly maintenance regimen of paliperidone palmitate. The present application also provides a method for treating psychiatric patients in need of a switching treatment to paliperidone palmitate in a sustained release formulation.

Novel conjugates and immunogens derived from risperidone and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of risperidone and paliperidone in biological fluids.

The invention relates to a novel dispersible tablet which is prepared from a certain amount of antipsychotic medicines or pharmaceutically acceptable salt or ester thereof or mixture thereof, a certain amount of selective serotonin reuptake inhibitors (SSRIs) and at least one of pharmaceutically acceptable carriers, wherein the antipsychotic medicines are aripiprazole, fluvoxamine, escitalopram, olanzapine, mirtazapine, clozapine, ziprasidone, mianserin, agomelatine, lurasidone, iloperidone, blonanserin, moclobemide, timiperone, palipeddone, trimipramine, carpipramine, lofepramine or mosapramine. The novel dispersible tablet is used for preventing, delaying or treating depression or schizophrenia of patients. Compared with common tablets or capsules, the novel dispersible tablet has the characteristics of quick and uniform dispersion, short disintegration time, quick medicine absorption, high bioavailability and good stability, and is convenient to take.

The invention relates to compounds of Formula I, wherein L¹, L², and L³ are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from paliperidone. The invention also relates to conjugates of a paliperidone hapten and a protein.

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone in a single lateral flow assay device.

Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, risperidone and paliperidone in a single lateral flow assay device.

A paliperidone double-layered osmotic pump controlled release tablet and the preparation method thereof are disclosed. The double-layered osmotic pump controlled release tablet comprises a rigid membrane, a push layer, a drug layer, an isolation layer and an aesthetic coating, wherein the rigid membrane contains a semi-permeable polymer, a porogen and/or a plasticizer and has one or more drug release orifices on one end, the push layer comprises an expanding material, an osmotic agent, a binder, a colorant and a lubricant, the drug layer contains a pharmaceutically active ingredient, a hydrophilic polymer, an osmotic agent, a colorant, a lubricant and an antistatic agent, the isolation layer is located between the inner surface of the rigid membrane and the push layer, and contains a hydrophilic polymer. The paliperidone double-layered osmotic pump controlled release tablet shows an increasing drug release rate at early stage and keeps a constant drug release rate at later stage.

The invention discloses a method for synchronously detecting seventeen antipsychotics in a blood sample. The method comprises the steps that the sample is extracted with a mixed solution of methanol and acetonitrile to obtain supernate, and after a solvent is removed from the supernate, the supernate is dissolved in a methanol aqueous solution and filtered to obtain a specimen; a high performanceliquid chromatography tandem mass spectrometry method is adopted to detect the specimen; the sample is serum or plasma, and the antipsychotics are amisulpride, aripiprazole, dehydro aripiprazole, chlorpromazine, clozapine, desmethylclozapine, fluphenazine, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, risperidone, 9-hydroxyrisperidone, sulpiride, ziprasidone and thioridazine; inthe high performance liquid chromatography, a mobile phase A is an aqueous solution of formic acid, and a mobile phase B is a methanol solution of the formic acid; and the mass spectrometry adopts amulti-ion reaction monitoring mode of positive ion electrospray ionization.

The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.

An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.

The present invention provides pure paliperidone as well as purification processes to obtain thereof.

The invention relate to a paliperidone slow release formulation and a preparation method thereof. The slow release formulation comprises a slow release skeleton, a film controlling coating layer, a thinner, a binding agent and a lubricant. Because the slow release formulation can be released at a continuous constant rate within a long period of time, a stable blood medicament level is provided and maintained in a stable and efficient range, the administration frequency is reduced, and the medicament plays the role of long action.

Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

The present invention provides a pharmaceutical composition, and provides for the use thereof for the treatment of excessive daytime sleepiness and/or a sleep disturbance in a psychiatric patient in need thereof. The pharmaceutical composition comprises a therapeutically effective amount of paliperidone, its pharmaceutically acceptable acid addition salts, enantiomeric forms, and esters thereof, together with a pharmaceutical carrier, and provides a relatively low plasma concentration variation of paliperidone to the psychiatric patient in need of treatment. The present invention also provides for the use of a pharmaceutical composition as defined above, in the preparation of a medicament for the treatment of excessive daytime sleepiness and/or a sleep disturbance in a psychiatric patient in need thereof.

The present invention relates to a process for preparing paliperidone from its intermediate 3-(2-chloroethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrrido[1,2-a]-pyrimidin-4-one.

The invention belongs to the technical field of pharmaceutical preparations and discloses a paliperidone bi-layer osmotic pump progressively-increased controlled release tablet and a preparation method thereof. The osmotic pump preparation comprises a tablet core and a semipermeable coating film, wherein the tablet core comprises a medicine containing layer and a boosting layer, the semipermeable coating film envelops the tablet core and is provided with medicine release holes, the medicine containing layer contains middle molecular polyoxyethylene (average molecular weight is 900, 000-1, 000,,000) and an osmotic active substance in a certain proportion so that the hydration rate of the medicine containing layer is proper, the release of the active medicine basically presents a progressively-increased release trend and the progressively-increased release can be kept for 14-24 hours by using the bi-layer tablet core and the single-layer coating. By adopting the preparation, the adverse reaction of the medicine can be reduced greatly, the compliance of a patient can be improved, simultaneously, the preparation is simple to prepare, the preparation process of the progressively-increased osmotic pump preparation is simplified greatly, and the preparation is more conductive to industrialized production.